Research Analysts Offer Predictions for PLX Q3 Earnings

Protalix BioTherapeutics, Inc. (NYSE:PLX) – HC Wainwright lowered their Q3 2027 EPS estimates for shares of Protalix BioTherapeutics in a research note issued on Tuesday, May 26th. HC Wainwright analyst R. Selvaraju now forecasts that the company will post earnings of $0.03 per share for the quarter, down from their prior estimate of $0.04. HC Wainwright has a “Buy” rating and a $12.00 price objective on the stock. The consensus estimate for Protalix BioTherapeutics’ current full-year earnings is $0.01 per share. HC Wainwright also issued estimates for Protalix BioTherapeutics’ Q4 2027 earnings at $0.07 EPS and FY2027 earnings at $0.12 EPS.

Protalix BioTherapeutics Stock Up 1.9%

Shares of NYSE:PLX opened at $2.14 on Wednesday. The stock has a market capitalization of $172.42 million, a PE ratio of -16.46 and a beta of -0.01. The firm’s 50 day moving average price is $2.16 and its 200-day moving average price is $2.20. Protalix BioTherapeutics has a twelve month low of $1.32 and a twelve month high of $3.19.

Institutional Trading of Protalix BioTherapeutics

Several institutional investors have recently made changes to their positions in PLX. R Squared Ltd purchased a new stake in shares of Protalix BioTherapeutics during the fourth quarter worth about $26,000. SG Americas Securities LLC bought a new stake in Protalix BioTherapeutics in the 4th quarter valued at $31,000. Bank of America Corp DE raised its holdings in shares of Protalix BioTherapeutics by 364,766.7% during the 2nd quarter. Bank of America Corp DE now owns 21,892 shares of the company’s stock worth $32,000 after acquiring an additional 21,886 shares in the last quarter. Marshall Wace LLP purchased a new stake in shares of Protalix BioTherapeutics during the 4th quarter worth approximately $34,000. Finally, BNP Paribas Financial Markets raised its holdings in shares of Protalix BioTherapeutics by 126.5% during the 3rd quarter. BNP Paribas Financial Markets now owns 15,215 shares of the company’s stock worth $34,000 after acquiring an additional 8,498 shares in the last quarter. Hedge funds and other institutional investors own 16.53% of the company’s stock.

About Protalix BioTherapeutics

Protalix BioTherapeutics (NYSE:PLX) is a clinical‐stage biopharmaceutical company focused on the development and manufacturing of recombinant therapeutic proteins through its proprietary ProCellEx® plant cell–based expression system. Headquartered in Carmiel, Israel, with operations in the United States, the company leverages its technology platform to produce complex biologics in a cost‐effective and scalable manner. Protalix’s core expertise lies in engineering plant cells to generate high‐quality therapeutic proteins for rare and specialty diseases.

The company’s first approved commercial product, ELELYSO® (taliglucerase alfa), received regulatory approval from the U.S.